Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia.

The clinical utility of pharmacogenomics (PGx) has been gaining traction alongside growing evidence that adverse drug reactions (ADRs) have significant genetic associations. Nala PGx Core is a multi-gene qPCR-based panel of 20 allele variants, comprising 18 SNPs and two copy number markers across four pharmacogenes - , , and . In this study, we validated the performance of Nala PGx Core against benchmark methods, on the Singaporean and Indonesian populations.